InvestorsHub Logo
Followers 14
Posts 1246
Boards Moderated 0
Alias Born 09/28/2022

Re: DoubleJ23 post# 631963

Monday, 09/18/2023 1:55:56 PM

Monday, September 18, 2023 1:55:56 PM

Post# of 697038
It’s the obvious choice for a partner with a checkpoint inhibitor or similar broad-attack immune stimulator. Any tumor type with a medium to high mutational burden (NSCLC, SCLC, bladder, H&N, etc) would be great candidates.

Not to mention patent cliffs. :)
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News